Clinical Trials Logo

Mesothelioma clinical trials

View clinical trials related to Mesothelioma.

Filter by:

NCT ID: NCT03412357 Recruiting - Clinical trials for Malignant Pleural Mesothelioma

MesoTRAP: A Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma.

MesoTRAP
Start date: August 10, 2017
Phase: N/A
Study type: Interventional

Malignant pleural mesothelioma is a cancer, caused by asbestos, which currently affects 2500 people in the UK each year. The main symptom is breathlessness caused by fluid building up in the space between the lung and the chest wall (pleural effusion). Treatment involves draining the fluid to allow the lung to re-expand (pleurodesis). However, sometimes tumour growth over the surface of the lung can prevent it from re-expanding. This 'trapped' lung results in fluid re-accumulation and repeated drainage which can lead to discomfort and multiple hospital visits. One approach to dealing with 'trapped' lung in mesothelioma is to insert a thin tube (Indwelling Pleural Catheter - IPC) into the space around the lung. The tube can stay in place for a long time allowing patients to drain off fluid at home. Another approach is a keyhole surgical operation (video-assisted thoracoscopic partial pleurectomy/decortication - VAT-PD) to remove as much tumour as possible from the lining of the lung to allow it to re-expand. While both approaches are currently offered in clinical practice, it is not known which of the two is most effective at relieving breathlessness. The only way to find out is to conduct a research trial comparing the two. The Investigators plan to do this, but first of all need to carry out a small pilot study to collect information necessary to help plan the full study.

NCT ID: NCT03399552 Recruiting - Clinical trials for Malignant Mesothelioma (MPM)

Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma

Start date: December 20, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to find out whether the combination of avelumab and SBRT is safe and what effect avelumab has on mesothelioma when given in combination with SBRT. In addition, a goal of this protocol is to study the effect of radiation therapy on the immune system. It is thought that radiation treatment may create a form of 'vaccine' against cancer inside the body and immunotherapy may improve this effect. The combination of radiation treatment and immunotherapy may be more effective against cancer than either radiation or immunotherapy alone.

NCT ID: NCT03393858 Recruiting - Cancer Clinical Trials

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma

Start date: December 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to investigate the clinical efficacy and toxicity of anti-PD-1 monoclonal antibody plus autologous dendritic cells-cytokine induced killer cell (DC-CIK) immunotherapy combined with hyperthermia in advanced malignant mesothelioma patients.Furthermore,to characterize response to therapy,the investigators intent to explore the predictive biomarker for this regimen.

NCT ID: NCT03319537 Recruiting - Mesothelioma Clinical Trials

Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma

Start date: October 5, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test any good and bad effects of activity pevonedistat taken alone, and also to test the safety of pevonedistat in combination with standard chemotherapy, pemetrexed/cisplatin.

NCT ID: NCT03290183 Recruiting - Thymoma Clinical Trials

Confocal Laser Endomicroscopy in Pleural Malignancies

Start date: August 28, 2017
Phase: N/A
Study type: Observational

To date, the different biopsy methods, such as CT-guided pleural biopsy, mediastinal biopsy, endosonography and thoracoscopy have their limitations in diagnosing pleural malignancies, such as mesothelioma. Sampling errors frequently occur resulting in the common histological finding of 'non-specific pleuritic/fibrosis', which presents a great uncertainty for clinicians and patients. Confocal laser endomicroscopy (CLE) provides real-time imaging on a cellular level, however data of CLE in pleural malignancies are lacking.

NCT ID: NCT03269227 Recruiting - Clinical trials for Malignant Pleural Mesothelioma

Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma

MesoRT
Start date: August 14, 2017
Phase: N/A
Study type: Interventional

This is a monocentric prospective study of radiotherapy using accelerated hypofractionation with Tomotherapy in Malignant Pleural Mesothelioma (MPM) patients after pleurectomy / decortication (P / D) or biopsy. The treatment will be delivered using Tomotherapy, that allows to adopt dose accelerated hypofraction criteria. Treatment duration is 5 consecutive days.

NCT ID: NCT03228537 Recruiting - Clinical trials for Epithelioid Mesothelioma

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

Start date: November 3, 2017
Phase: Phase 1
Study type: Interventional

This phase I pilot trial studies how well atezolizumab, pemetrexed disodium, cisplatin, and surgery with or without radiation therapy in treating patients with stage I-III pleural malignant mesothelioma. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab, pemetrexed disodium, and cisplatin before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving atezolizumab after surgery may kill any remaining tumor cells.

NCT ID: NCT03213301 Recruiting - Clinical trials for Malignant Pleural Mesothelioma, Advanced

Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.

Start date: September 28, 2017
Phase: Phase 2
Study type: Interventional

Aim of this study is to provide the "proof of concept" of efficacy and tolerability of lurbinectedin monotherapy in progressive malignant mesotheliomas.

NCT ID: NCT03212404 Recruiting - Clinical trials for Head and Neck Cancer

Phase 1 Study of CK-301 as a Single Agent in Subjects With Advanced Cancers

Start date: September 20, 2017
Phase: Phase 1
Study type: Interventional

CK-301 is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors. The primary objective of this study is to assess the safety, tolerability and preliminary efficacy of CK-301 when administered intravenously as a single agent to subjects with selected recurrent or metastatic cancers.

NCT ID: NCT03210298 Recruiting - Colorectal Cancer Clinical Trials

International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)

PIPACRegis
Start date: January 2016
Phase: N/A
Study type: Observational [Patient Registry]

Multicentric, international, web-based prospective documentation of the indications and results of Pressurized Aerosol Chemotherapy (so-called PIPAC or PITAC) for treating malignant pleural and peritoneal diseases. Indication is decided by the treating physician. There are no predefined inclusion or exclusion criteria.